Alvotech

Alvotech P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Alvotech (ALVO) as of Oct 17, 2026 is -10.51. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.10 — a change of 156.26% (lower).

P/FCF

-10.51

YoY

156.26%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alvotech is 2025 -10.51 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Alvotech was 2024 -4.10 . It decreases by 156.26% lower compared to the previous year.

The Alvotech P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
-12.48 USD
Jan 1, 2020
-13.97 USD
Jan 1, 2021
-4.48 USD
Jan 1, 2022
-3.34 USD
Jan 1, 2023
-3.36 USD
Jan 1, 2024
-4.10 USD
Jan 1, 2025
-10.51 USD
The Alvotech P/FCF history
YEARP/FCFYoY
-10.51+156.26%
-4.10+22.06%
-3.36+0.76%
-3.34-25.62%
-4.48-67.90%
-13.97+11.96%
-12.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alvotech Stock analysis

What does Alvotech do? Alvotech SA, listed on the stock market with ticker ALVO and ISIN LU2458332611, is a biotechnology company headquartered in Luxembourg. The company, which went public in November 2020, employs approximately 1,500 people. Alvotech focuses on the development and manufacturing of biosimilar medicines, aiming to provide affordable treatment options globally. Its pipeline includes eight biosimilar candidates targeting various therapeutic areas such as inflammatory diseases, oncology, and ophthalmology. Specific products in development include AVT02, a biosimilar to Humira (adalimumab), and AVT04, a biosimilar candidate to Stelara (ustekinumab). The company has established strategic commercial partnerships to expand its global reach, leveraging expertise in key markets including the United States, Europe, Japan, China, and regions across South America, Africa, and the Middle East. Alvotech's approach emphasizes the creation of high-quality biosimilars to address unmet medical needs in multiple disease areas. The company operates within the healthcare sector, specifically in biotechnology, and has positioned itself as a key player in the biosimilars market. With a focus on monoclonal antibodies, Alvotech aims to deliver innovative therapies that are both effective and cost-efficient for patients worldwide. Alvotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alvotech stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alvotech is -10.51 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alvotech changed from -4.10 to -10.51, representing a 156.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Alvotech since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Alvotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alvotech

All Key Metrics — Alvotech